




Searching News Database: CSL Behring
HSMN NewsFeed - 3 Jul 2020
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
HSMN NewsFeed - 23 Aug 2018
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
IDELVION(R) 3500 IU Vials Now Available to Provide Convenience to Patients
HSMN NewsFeed - 28 Aug 2017
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
HSMN NewsFeed - 21 Jul 2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA(R) (C1 Esterase Inhibitor Subcutaneous [Human])
HSMN NewsFeed - 3 Dec 2013
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
BioDelivery Sciences Announces Hiring of David Acheson as Vice President of Sales and Managed Markets
HSMN NewsFeed - 3 Sep 2013
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
CSL Behring Announces FDA Approval of a 10 g (50 mL) Vial Size for Hizentra(R)
HSMN NewsFeed - 28 Feb 2013
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
CSL Behring Receives FDA Approval to Expand the Indication for Corifact(R)
HSMN NewsFeed - 2 Aug 2012
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
HSMN NewsFeed - 27 Jan 2011
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
CSL Behring Receives National Marketing Authorization of Berinert(R) in Israel
HSMN NewsFeed - 26 Nov 2007
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
HSMN NewsFeed - 2 Apr 2007
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
FDA Approves Rhophylac(R) for the Treatment of Immune Thrombocytopenic Purpura (ITP)
HSMN NewsFeed - 1 Feb 2007
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor
CSL Behring and Bayer Extend Agreement for Supply of Helixate(R) Recombinant Coagulation Factor